Dupilumab

Woebot Health Names Brad Gescheider as Chief Commercial Officer

Retrieved on: 
Tuesday, September 27, 2022
Apps, Applications, Technology, Mental Health, Mobile, Wireless, Medical Devices, Health Technology, Software, Health, Data Management, Therapy, University, Software, Southern Methodist University, HITAC, Patient, Mental health, Intelligence, PatientsLikeMe, National, Quality of life, Blue Cross Blue Shield Association, Ecosystem, ONC, Methodist University, Overalls, GE Healthcare, McKesson Corporation, Multimedia, Health, Marketing, Medical device, Business development, Sanofi, Medicine, Management, Pharmaceutical industry, Dupilumab

Woebot Health today announced that it has appointed Brad Gescheider as its Chief Commercial Officer.

Key Points: 
  • Woebot Health today announced that it has appointed Brad Gescheider as its Chief Commercial Officer.
  • View the full release here: https://www.businesswire.com/news/home/20220927005322/en/
    Before joining Woebot Health, Gescheider was the Global Head of Digital Innovation and Patient Services for Sanofis Immunology business.
  • Gescheider has also held senior commercial strategy and operations roles at GE Healthcare, McKesson and PatientsLikeMe.
  • Woebot Health is the worlds first mental health ally for people and businesses, with products that put personal growth in peoples hands, wherever they are.

Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis

Retrieved on: 
Thursday, September 8, 2022
University, Dupilumab, Itch, Journal of the European Academy of Dermatology and Venereology, Skin, Union, Quality of life, Priority review, Atopic dermatitis, Congress, University of Miami, Prurigo nodularis, Review, Patient, Medical device, Pharmaceutical industry, Medical imaging, Venereology, Prurigo, Dermatology

These data from one of two pivotal trials in prurigo nodularis show Dupixent significantly reduced itch and skin lesions at 24 weeks.

Key Points: 
  • These data from one of two pivotal trials in prurigo nodularis show Dupixent significantly reduced itch and skin lesions at 24 weeks.
  • The late-breaking data presented at the EADV 2022 Congress are from the randomized, placebo-controlled Phase 3 PRIME trial, which met its primary and key secondary endpoints.
  • The safety results of the trial were generally consistent with the known safety profile of Dupixent in its approved dermatological indication.
  • AEs most commonly observed with Dupixent (5%) included nasopharyngitis (5% Dupixent, 4% placebo) and headache (5% Dupixent, 5% placebo).

Peptilogics Strengthens Leadership Team with Executive Appointments

Retrieved on: 
Wednesday, August 10, 2022
Health, Health Technology, Other Health, General Health, Pharmaceutical, Biotechnology, Dupilumab, Roemheld syndrome, Asthma, ACS, Risk, Johnson & Johnson, Mortality, Inflammation, Recurrence, Senior, Algorithm, HBM, Technology, Growth, Hospital, Cystic Fibrosis Foundation, Marketing, Patient, Therapy, Â, Founders Fund, Twitter, QIDP, Bacteria, Deep learning, Sanofi, DPM, Lead, Atopic dermatitis, MBA, Cystic fibrosis, Fast Track, LinkedIn, Hip, Cardiac arrest, Disease, Fine chemical, Pharmaceutical industry

Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, today announced two executive appointments to strengthen and expand its leadership team.

Key Points: 
  • Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, today announced two executive appointments to strengthen and expand its leadership team.
  • The addition of Dr. Deshpande to our executive team and the promotion of Dr. Pachuda reflects the growth of our organization and the necessary leadership to advance our pipeline and technology initiatives, said Jonathan Steckbeck, Ph.D., Founder and CEO of Peptilogics.
  • Dr. Deshpande will be responsible for the overall company strategy and business development at Peptilogics.
  • I am excited to work with this team to engineer peptide therapeutics that address unmet medical and access needs across the world.

Prime Medicine Expands Leadership Team with Key Appointments to Support Continued Growth and Advancement of Prime Editing Technology and Portfolio

Retrieved on: 
Thursday, July 28, 2022
Biotechnology, Health, Genetics, Science, Research, Prime editing, Sarepta Therapeutics, Novartis, Heidelberg University, Stanford University, MIT, MIT Sloan School of Management, BLA, Bain, Industry, Medicine, Research, Amondi, Associate, Bain & Company, Leadership, Merck, Technology, Business development, FDA, Company, Science and technology in Asia, Science, Senior, South China Global Talent Institute, Patient, Dublin City University, Bristol Myers Squibb, SVP, Doctor of Philosophy, Asclepius, Gene editing, Samsung, Bioverativ, Molecular biology, Regulatory affairs, HR, AAV, RNA, Pharmaceutical industry, Management, Biogen, Dupilumab, Golodirsen, Regulation, Sanofi

Together, they bring strong business acumen, extensive clinical and regulatory experience and leadership of successful teams that position us well to achieve our mission, said Keith Gottesdiener, M.D., Chief Executive Officer of Prime Medicine.

Key Points: 
  • Together, they bring strong business acumen, extensive clinical and regulatory experience and leadership of successful teams that position us well to achieve our mission, said Keith Gottesdiener, M.D., Chief Executive Officer of Prime Medicine.
  • These esteemed leaders have deep expertise across their respective focus areas, each of which is key to the advancement of our novel Prime Editing technology.
  • Richard Brudnick, Chief Business Officer, brings extensive industry experience, including leading successful business development transactions, across multiple stages of development and an array of therapeutic areas.
  • The company is deploying Prime Editing technology, a versatile, precise, efficient and broad gene editing technology, which is designed to make only the right edit at the right position within a gene.

Eosinophilic Esophagitis Clinical Trial Pipeline Analysis of 15+ Companies by DelveInsight

Retrieved on: 
Monday, July 25, 2022
Acquisition, AK002, Orphan drug, Diagnosis, Eosinophilic esophagitis, DBV Technologies, Enzyme inhibitor, RAPT, Atopic dermatitis, LANCL2, Dermatology, Esophagus, Ulcerative colitis, B cell, Lirentelimab, Disease, EOE, Gastroenterology, Child development stages, Human, Therapy, Alopecia areata, Safety, US, Pfizer, Arena Pharmaceuticals, Conditional sentence, Crohn's disease, LAS, FDA, Investigational New Drug, Patient, Cardiology, Pharmacokinetics, Bristol Myers Squibb, AstraZeneca, GlaxoSmithKline, Phase, Inflammation, Growth, Dupilumab, Eosinophil, IND, Pharmaceutical industry, Oil, Eosinophilic

LAS VEGAS, July 25, 2022 /PRNewswire/ -- DelveInsight's 'Eosinophilic Esophagitis Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline eosinophilic esophagitis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the eosinophilic esophagitis pipeline domain.

Key Points: 
  • Key players operating in the global eosinophilic esophagitis market include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline, AstraZeneca, Allakos, and others
    LAS VEGAS, July 25, 2022 /PRNewswire/ --DelveInsight's ' Eosinophilic Esophagitis Pipeline Insight 2022 'report provides comprehensive global coverage of available, marketed, and pipeline eosinophilic esophagitis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the eosinophilic esophagitis pipeline domain.
  • DelveInsight's eosinophilic esophagitis pipeline report depicts a robust space with 15+ active players working to develop 15 + pipeline therapies for eosinophilic esophagitis treatment.
  • Key eosinophilic esophagitis pipeline therapies in various stages of development includes Dupilumab, Benralizumab, CC-93538, APT-1011, AK002, ESO-101, Etrasimod, Mepolizumab, CALY-002, BT-11, Barzolvolimab, NDX33-o, SP16, Qi-201, Esomeprazole ODT, IRL201104, and others.
  • The company expects to initiate a randomized, double-blind, placebo-controlled Phase Ib study designed to evaluate the safety and pharmacokinetics of omilancor in patients with active Eosinophilic Esophagitis
    The eosinophilic esophagitis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage eosinophilic esophagitis products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the eosinophilic esophagitis pipeline landscape.

Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis

Retrieved on: 
Thursday, July 14, 2022
Disease, Anxiety, Eating, Pain scale, EOE, Eosinophilic esophagitis, Esophagus, Patient, Weight gain, Ageing, Steroid, Regeneron Pharmaceuticals, Human, Failure, Enzyme inhibitor, Growth, Vomiting, Caregiver, Pharmaceutical industry, Dupilumab

We are incredibly excited to share results from this Phase 3 pivotal trial evaluating Dupixent in young children suffering from eosinophilic esophagitis the first ever to show positive results across a variety of primary and secondary endpoints.

Key Points: 
  • We are incredibly excited to share results from this Phase 3 pivotal trial evaluating Dupixent in young children suffering from eosinophilic esophagitis the first ever to show positive results across a variety of primary and secondary endpoints.
  • In children, common symptoms of eosinophilic esophagitis include acid reflux, vomiting, abdominal discomfort, trouble swallowing, and a failure to thrive.
  • President and Chief Scientific Officer, Regeneron
    Dupixent is the first medicine to alleviate key signs of eosinophilic esophagitis in children as young as 1 year of age in a Phase 3 trial.
  • The positive results from this Phase 3 pediatric trial show Dupixent has the potential to improve signs of eosinophilic esophagitis and support healthy weight gain in children from their first birthday.

Spherix Global Insights Will Begin Tracking the Launch of Sanofi/Regeneron's Dupixent for the Treatment of Eosinophilic Esophagitis

Retrieved on: 
Thursday, June 16, 2022
Nephrology, FDA, Fluticasone, AstraZeneca, Gastroenterology, BMS, Dermatology, Polyp (medicine), Asthma, Ophthalmology, Takeda, Benchmarking, Atopic dermatitis, Pfizer, Patient, Eosinophilic esophagitis, Awareness, Neurology, Sinusitis, Pharmaceutical industry, EOE, Dupilumab

EXTON, Pa., June 16, 2022 /PRNewswire/ -- On May 20, 2022, the FDA approved Sanofi/Regeneron's Dupixent, the first therapy indicated to treat eosinophilic esophagitis (EoE). In response, Spherix Global Insights, an independent market intelligence firm, is initiating their Launch Dynamix™ service in order to track gastroenterologists' awareness, uptake, and perceptions of the IL4/13 inhibitor. The service will kick off in July.

Key Points: 
  • EXTON, Pa., June 16, 2022 /PRNewswire/ -- On May 20, 2022, the FDA approved Sanofi/Regeneron's Dupixent, the first therapy indicated to treat eosinophilic esophagitis (EoE).
  • In response, Spherix Global Insights, an independent market intelligence firm, is initiating their Launch Dynamix service in order to track gastroenterologists' awareness, uptake, and perceptions of the IL4/13 inhibitor.
  • Spherix has been monitoring the EoE treatment landscape for the past two years through their Market Dynamix service.
  • Aside from the Launch Dynamix Dupixent tracking, Spherix will publish the third annual Market Dynamix report covering the EoE landscape later this year.

Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis

Retrieved on: 
Tuesday, June 7, 2022
Caregiver, Siliceous ooze, Human, Regeneron Pharmaceuticals, Safety, Food, Ageing, Conditional sentence, Disease, Atopic dermatitis, Itch, Pain, Red, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Priority review, FDA, Bleeding, TCS, Patient, Risk, Review, Immune system, European Medicines Agency, Association, Skin, Population, Rash, Crust (geology), IGA, Psoriasis Area and Severity Index, Management, Vaccine, Birth control, Dietary supplement, Dupilumab

In the U.S., more than 75,000 children aged 5 years and younger have uncontrolled moderate-to-severe disease and are most in need of new treatment options.

Key Points: 
  • In the U.S., more than 75,000 children aged 5 years and younger have uncontrolled moderate-to-severe disease and are most in need of new treatment options.
  • These young people, and their families, often struggle to cope with the significant impact itch can have on them.
  • This approval means that Dupixent, with its well-established safety and efficacy profile, is now available to some of the youngest people living with this disease.
  • The safety profile of Dupixent observed through 16 weeks in children aged 6 months to 5 years was similar to the safety profile in patients 6 years and older with atopic dermatitis.

FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis

Retrieved on: 
Tuesday, June 7, 2022
Caregiver, Siliceous ooze, M.D, Human, Regeneron Pharmaceuticals, Safety, International development, Food, Child, Ageing, Conditional sentence, Disease, Atopic dermatitis, Itch, Pain, Senior, Red, Priority review, FDA, Bleeding, TCS, Patient, Immune system, Quality of life, NASDAQ, European Medicines Agency, Association, Population, Inflammation, Crust (geology), IGA, Skin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Psoriasis Area and Severity Index, Vaccine, Dietary supplement, Birth control, Sanofi, Dupilumab

TARRYTOWN, N.Y. and PARIS, June 7, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Regulatory filings for this age group are underway by the European Medicines Agency and regulatory authorities in additional countries.

Key Points: 
  • Moderate-to-severe atopic dermatitis may also significantly impact the quality of life of a young child and their caregivers.
  • The safety profile of Dupixent observed through 16 weeks in children aged 6 months to 5 years was similar to the safety profile in patients 6 years and older with atopic dermatitis.
  • In children younger than 12 years of age, Dupixent should be administered by a caregiver if given at home.
  • It is not known if DUPIXENT is safe and effective in children with atopic dermatitis under 6 months of age.

FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

Retrieved on: 
Friday, May 20, 2022
Journal of Transportation Engineering, Part B: Pavements, Office of Inspector General, U.S. Department of Health and Human Services, Hypersensitivity, Center for Drug Evaluation and Research, Disease, Ageing, Public health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Research, Keratitis, Arthralgia, Asthma, Sinusitis, Adolescence, Cosmetics, Parasitism, Patient, Dysphagia, Multimedia, Vaccine, China Biologic Products, Esophagus, Human services, Clinical trial, Adult, FDA, Polyp (medicine), Regeneron Pharmaceuticals, Eosinophilic esophagitis, Center, Smokeless tobacco, Animal, Dietary supplement, Safety, DSQ, Division, Allergy, Eosinophil, Maintenance, Conjunctivitis, Respiratory tract, Atopic dermatitis, Pharmaceutical industry, Part, EOE, Gastroenterology, Dupilumab

Today's action marks the first FDA approval of a treatment for EoE.

Key Points: 
  • Today's action marks the first FDA approval of a treatment for EoE.
  • "Today's approval will fulfill an important unmet need for the increasing number of patients with eosinophilic esophagitis."
  • EoE is a chronic inflammatory disorder in which eosinophils, a type of white blood cell, are found in the tissue of the esophagus.
  • In adults and adolescent patients with EoE, common symptoms include difficulty swallowing, difficulty eating, and food getting stuck in the esophagus.